NEW YORK (GenomeWeb News) – Novo Nordisk has licensed gene expression technology from TET Systems for use in its research activities, TET Systems said.

Under the agreement, Novo Nordisk will use TET Systems technology at the Hagedorn Research Institute, which handles the drug developer's internal research activities.

Heidelberg, Germany-based TET Systems holds six patent families of intellectual property covering methods to control gene expression in higher organisms.

Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.